Anlon Healthcare files IPO papers with SEBI for third time with no change in offer size

Anlon Healthcare IPO

Anlon Healthcare, which manufactures chemical for the pharmaceutical formulations, has filed draft red herring prospectus with the SEBI again, for raising funds via initial public offering.

This is the third time it approached SEBI with draft papers for IPO. In the first time in October 2024, Gujarat-based Anlon had filed IPO papers, but the SEBI had returned those draft offer documents in December 2024. Again on February 20 this year, Anlon had filed draft papers, however, it has withdrawn those papers from the capital markets regulator on March 28 this year, amid subdued and volatile equity markets.

Meanwhile, the company has not changed its IPO size in all those three filings, which will consist of solely fresh issue of 1.4 crore equity shares.

Anlon Healthcare intends to utilise fresh issue proceeds mainly for expansion of manufacturing facility, repayment of debt, working capital requirements, and general corporate purposes.

The company manufactures advance pharmaceutical intermediates which serves as raw material or key starting material in the manufacturing of active pharmaceutical ingredients; and active pharmaceutical ingredients (APIs) which serves as a raw material for pharmaceutical formulations in preparation of various type of finished dosage formula (FDF).

Interactive Financial Services as a merchant banker will handle the public issue.